Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage
biotechnology company seeking to develop differentiated biologics
for the treatment of atopic dermatitis, chronic obstructive
pulmonary disease, asthma and other inflammatory and immunology
indications (Apogee or the Company), today announced that it has
commenced an underwritten public offering of approximately $350.0
million of shares of its common stock. In addition, Apogee expects
to grant the underwriters a 30-day option to purchase up to an
additional $52.5 million of shares of common stock at the public
offering price, less underwriting discounts and commissions. The
proposed public offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed or as to the actual size or terms of the offering.
All of the securities are being offered by Apogee.
Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD
Cowen, and Stifel are acting as joint book-running managers for the
proposed offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission (SEC) but has not
yet become effective. These securities may not be sold, nor may
offers to buy be accepted, prior to the time the registration
statement becomes effective. This offering will be made only by
means of a written prospectus. A copy of the preliminary prospectus
relating to the offering may be obtained, when available, from:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY 10022, by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com; BofA
Securities, NC1-022-02-25, Attention: Prospectus Department, 201
North Tryon, Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282, by
telephone at: (866) 471-2526, by facsimile: (212) 902-9316, or by
email at Prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by telephone at (833)
297-2926, or by email at Prospectus_ECM@cowen.com; or Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720, or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company
seeking to develop differentiated biologics for the treatment of
atopic dermatitis (AD), chronic obstructive pulmonary disease
(COPD), asthma and other inflammatory and immunology indications
with high unmet need. Apogee’s antibody programs are designed to
overcome limitations of existing therapies by targeting
well-established mechanisms of action and incorporating advanced
antibody engineering properties to optimize half-life and other
properties. The Company’s two most advanced programs are APG777 and
APG808, which are being initially developed for the treatment of AD
and COPD, respectively. Based on a broad pipeline and depth of
expertise, the company believes it can deliver value and meaningful
benefit to patients underserved by today’s standard of care.
Forward-Looking Statements
Certain statements in this press release may constitute
“forward-looking statements” within the meaning of the federal
securities laws, including, but not limited to, Apogee’s
expectations regarding the proposed offering, including the timing,
size, structure and completion of the proposed offering on the
anticipated terms. Words such as “may,” “might,” “will,”
“objective,” “intend,” “should,” “could,” “can,” “would,” “expect,”
“believe,” “design,” “estimate,” “predict,” “potential,” “develop,”
“plan” or the negative of these terms, and similar expressions, or
statements regarding intent, belief, or current expectations, are
forward-looking statements. While Apogee believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties (including, without limitation, those set forth in
Apogee’s filings with SEC, many of which are beyond the Company’s
control and subject to change). Actual results could be materially
different. Risks and uncertainties include: global macroeconomic
conditions and related volatility, expectations regarding the
initiation, progress, and expected results of the Company’s
preclinical studies, clinical trials and research and development
programs; expectations regarding the timing, completion and outcome
of the Company’s clinical trials; the unpredictable relationship
between preclinical study results and clinical study results; the
timing or likelihood of regulatory filings and approvals; liquidity
and capital resources; and other risks and uncertainties identified
in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the SEC on March 5, 2024, and
subsequent disclosure documents we may file with the SEC. Apogee
claims the protection of the Safe Harbor contained in the Private
Securities Litigation Reform Act of 1995 for forward-looking
statements. Apogee expressly disclaims any obligation to update or
alter any statements whether as a result of new information, future
events or otherwise, except as required by law.
Investor Contact:Noel KurdiVP, Investor
RelationsApogee TherapeuticsNoel.kurdi@apogeetherapeutics.com
Media Contact:Dan Budwick1AB
Mediadan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Apogee Therapeutics (NASDAQ:APGE)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024